Table 4.

Risk of adverse outcomes in the untreated (Non-OAC) group as compared to the anticoagulated (OAC) group in patients with CHA₂DS₂-VASc score ≥2 if male and ≥3 if female

	Non-OAC	OAC
	(N = 2851)	(N = 2891)	Odds ratio
Outcome	n (%)	n (%)	(95%CI)
All-cause death	148 (5.2)	40 (1.4)	3.90 (2.74–5.56)
TE events	59 (2.1)	24 (0.8)	2.54 (1.57–4.09)
Intracranial bleeding	6 (0.2)	4 (0.1)	1.53 (0.43–5.43)
Extracranial major bleeding	35 (1.2)	24 (0.8)	1.49 (0.89–2.51)

CI, confidence interval; OAC, oral anticoagulation; TE, thromboembolic.